By: ifood.tv

AZD9291 First Time In Patients Ascending Dose Study

Mar 01, 2013 No Comments by

This study will treat patients with advanced NSCLC who have already received at least one
course of specific anti-cancer treatment but the tumour has started to re-grow following
that treatment. This is the first time this drug has ever been tested in patients, and so it
will help to understand what type of side effects may occur with the drug treatment, it
will measure the levels of drug in the body, it will also measure the anti-cancer activity.
By using these pieces of information together the best dose of this drug to use in further
clinical trials will be selected.

Clinical Trial Conditions: Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer

Treatments in this Clinical Trial : AZD9291

Clinical Trial Phase: Phase 1

Eligible Clinical Trial Participant Age : Between 0 years to 100 years

Can Healthy Volunteers Participate: No

Clinical Trial Lead Sponsor: AstraZeneca

Detailed Clinical Trial Description: This study will treat patients with advanced NSCLC who have already received at least one
course of specific anti-cancer treatment but the tumour has started to re-grow following
that treatment. This is the first time this drug has ever been tested in patients, and so it
will help to understand what type of side effects may occur with the drug treatment, it
will measure the levels of drug in the body, it will also measure the anti-cancer activity.
By using these pieces of information together the best dose of this drug to use in further
clinical trials will be selected.

The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01802632

New Clinical Trial

About the author

The author didnt add any Information to his profile yet
No Responses to “AZD9291 First Time In Patients Ascending Dose Study”

Leave a Reply

By: ifood.tv